长期治疗慢性心力衰竭的左心室辅助装置的经济方面
Henryk Welp1,2, Jürgen Sindermann1,2,3, Angelo Maria Dell'Aquila1
1Department of Cardiothoracic Surgery, University Hospital of Muenster, Albert Schweitzer Campus 1, A1, 48149, Muenster, Germany.
ESC heart failure
|May 21, 2024
概括
左心室辅助器械 (LVAD) 治疗改善了末期心力衰竭患者的生存率,但显著增加了医疗保健成本. 需要进一步的研究来了解这些救命设备的长期经济影响.
科学领域:
- 心脏病学 心脏病学
- 卫生经济学 卫生经济学
- 医疗技术 医疗技术 医学技术
背景情况:
- 末期心力衰竭的患病率越来越高.
- 供体器官短缺导致机械循环支持的需求.
- 在左心室辅助装置 (LVAD) 技术的进步.
研究的目的:
- 评估与左心室辅助器件 (LVAD) 治疗相关的长期成本.
- 确定导致高治疗费用的特定诊断.
- 评估LVAD植入在心力衰竭管理中的经济影响.
主要方法:
- 对前性收集的数据进行回顾性分析.
- 包括在2022年3月之前接受第二代或第三代LVAD的患者.
- 确定人口统计数据,生存率,收入和案例组合点.
主要成果:
- 包括163名患者,平均年龄为52岁;男性75.5%.
- 平均存活时间为1458天;平均住院治疗时间为70天.
- 显著的成本:每名患者的植入物住院 (193,192美元),再入院 (52,069美元) 和门诊护理 (53,196美元).
结论:
- 左心室辅助装置 (LVAD) 植入可提高患者的生存率,但会大幅增加治疗费用.
- 接受LVAD治疗的末期心力衰竭患者需要承担相当大的长期医疗费用.
- 进一步的多中心研究至关重要,以充分了解LVAD治疗对医疗保健系统的长期经济负担.
相关概念视频
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421


